Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
Not Confirmed
Not Confirmed
07-09 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Industry Trade Show
Not Confirmed
07-09 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/fda-s-landmark-approvals-of-bms-schizo-med-madrigal-s-mash-drug-us-16-5-bn-catalent-buyout-make-it-to-top-10-news-of-2024
18 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-asc47-a-muscle-preserving-weight-loss-drug-candidate-for-treatment-of-obesity-in-combination-with-semaglutide-demonstrated-superior-weight-loss-to-semaglutide-monotherapy-in-a-preclinical-model-302335013.html
12 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral-tablet-for-treatment-of-acne-302302294.html
07 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-promising-results-from-a-phase-i-study-in-australia-for-first-in-class-muscle-preserving-weight-loss-drug-candidate-asc47-for-the-treatment-of-obesity-302298659.html
17 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-enters-the-obesity-drug-space-with-announcement-of-two-ongoing-us-phase-i-clinical-trials-utilizing-its-small-molecule-glp-1r-agonist-asc30-for-both-once-monthly-subcutaneous-injection-and-once-daily-oral-tablet-for-the-302249778.html
03 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-strategic-decisions-on-fxr-agonist-asc42-302107029.html
03 Apr 2024
// Ayisha Sharma ENDPTS
https://endpts.com/ascletis-pharma-scraps-liver-disease-program-another-reverse-merger/
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?